Search...
Fascinating update on eye cancer at AAO 2022. Ocular melanoma or, more specifically, uveal melanoma is a relatively rare but deadly cancer. Despite significant improvements in local treatments of primary tumors, up to 50% of patients develop metastasis. What if a patient’s risk for metastasis could be determined by a simple blood test? That’s the ultimate goal of a “liquid biopsy” for uveal melanoma. Liquid biopsy involves the sampling of tumor-derived molecules in body fluids such as blood. This would be a big improvement over an invasive biopsy, which carries rare, but severe complications, including hemorrhage, retinal detachment, and cataract. A liquid biopsy would provide not only biomarkers of disease, but also tumor-derived molecules that can be exploited noninvasively to better understand the disease. It’s not yet ready for prime time, but it’s a developing and exciting field. Didn’t make it to AAO 2022? You can still register until Jan. 17, 2023 Learn more aao.org/2022 If you registered for the meeting, The AAO 2022 Virtual Meeting platform is open through 11:59 p.m. ET on Jan. 31, 2023. After Jan. 31, you will still be able to access sessions on-demand and claim CME credit (professional attendees only) through Aug. 1, 2023.
By aaoeye
Published
From the Health Care Hub community. Empowering medical learners with innovative insights for healthcare advancement.
Posted in Ophthalmologists 👁️. Explore innovative insights and empower medical learners for healthcare advancements.
8 views
1 likes